Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Feb;45(2):247-258.
doi: 10.1002/pd.6729. Epub 2024 Dec 20.

Cost-Effectiveness Analysis of a Novel Fetal Vesicoamniotic Shunt-The Vortex Shunt

Jamie A Schlacter  1 , Enrico Danzer  2   3 , Claire H Packer  4 , Eric Johnson  5 , Aaron B Caughey  6 , Yair J Blumenfeld  7 , Kunj R Sheth  8
Affiliations

Cost-Effectiveness Analysis of a Novel Fetal Vesicoamniotic Shunt-The Vortex Shunt

Jamie A Schlacter et al. Prenat Diagn. 2025 Feb.

Abstract

Objective: We estimated the potential outcomes, costs, and cost-effectiveness of the Vortex shunt, a novel fetal vesicoamniotic shunt (VAS), compared to standard shunts for treating fetal lower urinary tract obstruction (LUTO).

Method: We designed a decision-analytic model comparing the Vortex shunt to current shunts using a theoretical cohort of 1000 pregnancies equivalent to the annual U.S. LUTO cases. Current literature indicates a 50% dislodgement risk and a 36% end-stage renal disease (ESRD) probability for current shunts versus the Vortex shunt's expected 10% dislodgement risk and 18% ESRD rate from pre-clinical studies. Outcomes included preterm delivery, preterm premature rupture of membrane (PPROM), ESRD, neurodevelopmental delay (NDD), neonatal death, costs, and quality-adjusted life years (QALYs). We derived model inputs from the literature and conducted sensitivity analyses.

Results: Of 1000 theoretical LUTO pregnancies, the Vortex shunt resulted in 70 fewer cases of ESRD, 110 fewer preterm deliveries, 50 fewer episodes of PPROM, and 10 fewer children with NDD. The Vortex shunt was the dominant strategy with higher QALYs and estimated lifetime savings of $168,520 for each fetus undergoing VAS. The Vortex shunt was cost-effective 98% of the time.

Conclusion: Our theoretical model suggests that the Vortex shunt is cost-effective compared to current shunts.

PubMed Disclaimer

References

    1. G. Malin, A. M. Tonks, R. K. Morris, J. Gardosi, and M. D. Kilby, “Congenital Lower Urinary Tract Obstruction: A Population‐Based Epidemiological Study,” BJOG 119, no. 12 (2012): 1455–1464, https://doi.org/10.1111/j.1471‐0528.2012.03476.x.
    1. D. O. Anumba, J. E. Scott, N. D. Plant, and S. C. Robson, “Diagnosis and Outcome of Fetal Lower Urinary Tract Obstruction in the Northern Region of England,” Prenatal Diagnosis 25, no. 1 (2005): 7–13, https://doi.org/10.1002/pd.1074.
    1. R. K. Morris, G. L. Malin, E. Quinlan‐Jones, et al., “The Percutaneous Shunting in Lower Urinary Tract Obstruction (PLUTO) Study and Randomised Controlled Trial: Evaluation of the Effectiveness, Cost‐Effectiveness and Acceptability of Percutaneous Vesicoamniotic Shunting for Lower Urinary Tract Obstruction,” Health Technology Assessment 17, no. 59 (2013): 1–232, https://doi.org/10.3310/hta17590.
    1. D. K. Nakayama, M. R. Harrison, and A. A. de Lorimier, “Prognosis of Posterior Urethral Valves Presenting at Birth,” Journal of Pediatric Surgery 21, no. 1 (1986): 43–45, https://doi.org/10.1016/s0022‐3468(86)80651‐0.
    1. R. K. Morris, G. L. Malin, E. Quinlan‐Jones, et al., “Percutaneous Vesicoamniotic Shunting Versus Conservative Management for Fetal Lower Urinary Tract Obstruction (PLUTO): A Randomised Trial,” Lancet 382, no. 9903 (2013): 1496–1506, https://doi.org/10.1016/s0140‐6736(13)60992‐7.

Publication types

LinkOut - more resources